ISIS Pharmaceuticals Initiates Clinical Study in Infants with Spinal Muscular Atrophy
Originally published on April 23, 2013. Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced in April the initiation of a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy (SMA). The study, which will begin enrolling patients soon, is a Phase 2 study in eight patients with infantile-onset SMA. The study, which initiates the Phase […]
ISIS Pharmaceuticals Initiates Clinical Study in Infants with Spinal Muscular Atrophy Read More »